Recommendations for bone-directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting.

The role of anti-resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone-specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM). Recommendations for bone-specific treatment were given at 29/365 MDMs (7.9%); 44.8% were confirmed to have received the recommended therapy. Bone-specific treatment recommendations were infrequent; there is a need for more data on the role of anti-resorptive agents in this group.